Compare Regeneron Pharmaceuticals Inc (REGN) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Energy Select Sector SPDR Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Energy Select Sector SPDR Fund trades at $64.94 (market cap $40.93B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Energy Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| REGN | XLE | |
|---|---|---|
Market Cap | $76.40B | $40.93B |
Volume | 626,381 | 26,195,130 |
Sector | Health | — |
52-Week High | $852.03 | $65.93 |
52-Week Low | $557.73 | $42.61 |
Typical Hold Time | 107 Days | 67 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
XLE trades at $63.38, down 0.58% with a bullish technical outlook supported by moving averages. The energy ETF faces mixed sentiment amid geopolitical tensions and oil price volatility, with recent news highlighting Middle East conflicts and strategic reserve releases. Technical indicators show strong momentum with ADX signals in buy territory while oscillators remain neutral.
The energy sector faces headwinds from potential oil price corrections and geopolitical risks, though XLE's technical strength suggests near-term upside potential. Key risks include oil market volatility and Federal Reserve policy impacts, while institutional interest remains focused on energy infrastructure alternatives with higher yields.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
